You just read:

Application Submitted to the EMA to Expand the Therapeutic Indication for IMBRUVICA® (ibrutinib) to Include Treatment of Waldenström's Macroglobulinemia

News provided by

Janssen-Cilag International NV

01 Dec, 2014, 08:00 GMT